Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979544 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
A Phase 3 study, sponsored by Lipocine.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT06979544 is a Phase 3 study that has completed, run by Lipocine. The registered enrollment target is 90 participants.
The verdict
NCT06979544, a Phase 3 study, has completed, sponsored by Lipocine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause * If LPCN 1154A reduces anxiety symptoms in subjects with severe PPD
Interventions
- DRUG Placebo
- DRUG LPCN 1154A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06979544
The ClinicalTrials.gov registry entry for NCT06979544 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lipocine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06979544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06979544 about?
NCT06979544 is a clinical study titled "A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD". The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cau...
What is the current status of trial NCT06979544?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2025-06-16. Estimated completion is 2026-02-17.
What interventions are being tested in trial NCT06979544?
The interventions under investigation include: Placebo (DRUG), LPCN 1154A (DRUG).
Who is sponsoring clinical trial NCT06979544?
This trial is sponsored by Lipocine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.